Form 4: Balchem CEO Harris Boosts Stake with Equity Awards
Insider Transaction Report
Balchem Corporation's Chairman, President & CEO, Theodore L. Harris, reported significant equity awards, including restricted stock, performance units, and stock options, alongside shares withheld for tax obligations.
Summary
- Theodore L. Harris, Balchem Corporation's Chairman, President & CEO, reported multiple transactions involving the company's common stock and stock options.
- On February 11, 2026, Harris acquired 7,350 shares of common stock as restricted stock, which will vest over a three-year period (25% on the first anniversary, 25% on the second, and 50% on the third anniversary of the grant date).
- Also on February 11, 2026, 18,291 shares of common stock vested from performance stock units for the 2023-2025 performance period, including 306 dividend equivalent shares.
- To cover tax requirements upon the vesting of performance stock units, 9,358 shares were disposed of at a price of $178.68 per share on February 11, 2026.
- On February 12, 2026, an additional 844 shares were withheld to cover withholding taxes due upon the vesting of restricted shares granted on February 12, 2025, at a price of $177.49 per share.
- Harris also acquired 26,900 stock options on February 11, 2026, with an exercise price of $178.68. These options vest over three years (20% Year 1, 40% Year 2, and 40% Year 3) and expire on February 11, 2036.
- Following these transactions, Harris directly owns 91,373 shares of common stock and 26,900 stock options.
- Indirect ownership includes 2,007 shares in a 401(k) Plan and 1,022.58 shares held by a trust, for which Harris disclaims beneficial ownership except for any pecuniary interest.
- The transactions were made pursuant to a Rule 10b5-1(c) plan.
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a moderately positive development, reflecting ongoing executive compensation and performance-based awards, which generally align management's interests with shareholders. The withholding of shares for taxes is a standard, neutral event.
Positives
- Acquisition of 7,350 restricted shares of common stock, aligning management's interests with shareholders.
- Vesting of 18,291 performance stock units, including 306 dividend equivalent shares, indicating achievement of performance targets for the 2023-2025 period.
- Grant of 26,900 stock options, providing long-term incentive for the CEO.
- The transactions were conducted under a Rule 10b5-1(c) plan, suggesting pre-planned and not opportunistic trading.
Negatives
- Disposition of 9,358 shares at $178.68 and 844 shares at $177.49 to cover tax obligations upon vesting, which reduces the immediate net share gain.
Future Outlook
NA
Industry Context
StockSavvy.ai notes that the grant and vesting of equity awards, such as restricted stock, performance units, and stock options, are standard practices in executive compensation across various industries, designed to align executive incentives with long-term shareholder value creation. These types of awards are common in the specialty chemicals and nutrition industry, where Balchem operates, to retain key talent and reward performance.
Related Party Transactions
- Indirect ownership of 1,022.58 shares in a trust for the benefit of the Reporting Person's mother, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership except to the extent of his pecuniary interest.
Stakeholder Impact
- Shareholders: The equity awards align the CEO's financial interests with the long-term performance of the company, potentially encouraging decisions that enhance shareholder value.
- Employees: The compensation structure for the CEO may reflect broader compensation philosophies within the company, potentially influencing employee morale and retention.
Next Steps
- Vesting of 7,350 restricted shares over a three-year period (25% on first anniversary, 25% on second, 50% on third anniversary of 02/11/2026).
- Vesting of 26,900 stock options over three years (20% Year 1, 40% Year 2, 40% Year 3 from 02/11/2026).
Key Dates
| Date | Description |
|---|---|
| 02/12/2025 | Grant date of restricted shares, which vested on 02/12/2026, leading to tax withholding. |
| 02/11/2026 | Transaction date for acquisition of restricted stock, vesting of performance stock units, disposition of shares for tax, and acquisition of stock options. |
| 02/12/2026 | Transaction date for disposition of shares for tax related to restricted shares granted on 02/12/2025. |
| 02/13/2026 | Signature date of the reporting person's attorney-in-fact. |
| 02/11/2036 | Expiration date of the acquired stock options. |
Recommendation
holdThis Form 4 filing details routine executive compensation, including the grant and vesting of equity awards and the associated tax withholdings. While the awards align management's interests with shareholders, these are expected events and do not provide new fundamental information that would significantly alter the investment thesis for Balchem Corporation. Therefore, a 'hold' recommendation is appropriate, pending further fundamental analysis.
Keywords
Balchem Corporation, BCPC, Theodore L Harris, SEC Form 4, Insider Trading, Restricted Stock, Performance Stock Units, Stock Options, Equity Awards, Executive Compensation, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.